Taking these previous observations into account, and knowing that the invasive P-cadherin cells have activation of the SRC pathway [34–37], we tested the functional effect of dasatinib in P-cadherin overexpressing tumour cells, in order to evaluate the impact of this adhesion molecule as a therapeutic biomarker in BLBC. Here, CDH3 is linked to neoplasm.